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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 87, Revision 2 
(FGE.87Rev2): Consideration of bicyclic secondary alcohols, ketones and 
related esters evaluated by JECFA (63rd meeting) structurally related to 
bicyclic secondary alcohols, ketones and related esters evaluated by EFSA 
in FGE.47Rev1 (2008)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of 19 bicyclic secondary alcohols, ketones and related esters evaluated by the JECFA at the 63rd meeting 
in 2004. This revision of FGE.87 is made due to inclusion of two additional substances Nookatone [FL-no: 
07.089] and 4,4a,5,6-tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.136] cleared for genotoxicity concern 
in FGE.213 Rev1. The substances were evaluated through a stepwise approach that integrates information on 
structure-activity relationships, intake from current uses, toxicological threshold of concern, and available data 
on metabolism and toxicity. The Panel agrees with the application of the Procedure as performed by the JECFA 
for all substances considered in this FGE and for 18 substances the Panel agrees with the JECFA conclusion, 
“No safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach. For one 
substance [FL-no: 07.136], a production volume for Europe is not available, which precludes the finalisation of 
the evaluation by EFSA of this substance. Besides the safety assessment of these flavouring substances, the 
specifications for the materials of commerce have also been considered for the substances evaluated through the 
Procedure and for all 19 substances, the information is adequate. 
© European Food Safety Authority, 2014 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2014-00348 and EFSA-Q-2014-00349, adopted on 25 
September 2014. 
2  Panel members: Claudia Bolognesi, Laurence Castle, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul Fowler, Roland Franz, 
Konrad Grob, Rainer Gürtler, Trine Husøy, Wim Mennes, Maria Rosaria Milana, André Penninks, Vittorio Silano, Andrew 
Smith, Maria de Fátima Tavares Poças, Christina Tlustos, Fidel Toldrá, Detlef Wölfle and Holger Zorn. Correspondence: 
fip@efsa.europa.eu   
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Trine Husøy, Wim Mennes, Gerard 
Mulder and Harriet Wallin for the preparatory work on this scientific opinion and the hearing experts: Vibe Beltoft, Pia 
Lund and Karin Nørby and EFSA staff: Maria Carfí, Annamaria Rossi and Kim Rygaard Nielsen for the support provided 
to this scientific opinion. 
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SUMMARY 
Following a request from the European Commission the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver  scientific advice to the 
Commission on the implications for human health of chemically defined flavouring substances used in 
or on foodstuffs in the Member States. In particular, the CEF Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
This consideration deals with 19 bicyclic secondary alcohols, ketones and related esters, which are in 
the Register and which were evaluated by the JECFA at its 63rd meeting.  
The revision is made due to consideration of two additional substances nootkatone and 4,4a,5,6-
tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.089 and 07.136] compared to the previous 
version. These two substances are α,β-unsaturated alicyclic ketones which have been considered with 
respect to genotoxicity in FGE.213Rev1, and the Panel concluded that the data available ruled out the 
concern for genotoxicity and thus concluded that the two substances can be evaluated through the 
Procedure in this FGE.87Rev2.  
The Panel concluded that all 19 substances are structurally related to the group of bicyclic secondary 
alcohols, ketones and related evaluated by EFSA in the Flavouring Group Evaluation 47 
(FGE.47Rev1). 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 19 bicyclic 
secondary alcohols, ketones and related esters. It was concluded at step A3 of the Procedure that 18 
substances do not pose a safety concern when used as flavouring substances at estimated levels of 
intake, based on the MSDI approach. For one substance [FL-no: 07.136], the evaluation through the 
Procedure could not be finalised because of absence of an EU production volume. 
For all 19 substances evaluated through the Procedure use levels are needed to calculate the modified 
Theoretical Added Maximum Daily Intake (mTAMDIs )in order to identify those flavouring 
substances that need more refined exposure assessments and to finalise the evaluation. 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications are available for all the materials of commerce, however, a production volume for EU 
for substance [FL-no: 07.136] is not available, which precludes the finalisation of the evaluation by 
EFSA of this substance. 
For the remaining 18 JECFA evaluated bicyclic secondary alcohols, ketones and related esters [FL-no: 
02.016, 02.038, 02.059, 02.100, 02.101, 07.089, 07.153, 07.159, 09.017, 09.082, 09.131, 09.153, 
09.176, 09.218, 09.269, 09.319, 09.456 and 09.457] the Panel agrees with the JECFA conclusion: “No 
safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA concluded that a genotoxic potential of the α,β-unsaturated precursor, beta-ionyl acetate [FL-no: 
09.305] in FGE.213 could not be ruled out. 
Information on four representative materials has now been submitted by the European Flavour 
Association. These are beta-ionone [FL-no: 07.008], maltol [FL-no: 07.014], nootkatone [FL-no: 
07.089] and 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109]. 
This information is intended to cover also the re-evaluation of the following eight substances from 
FGE.19 subgroup 2.7: 
• 4-(2,2,6-Trimethyl-1-cyclohexenyl)but-3-en-2-ol [FL-no: 02.106] 
• Methyl-beta-ionone [FL-no: 07.010] 
• Beta-Isomethylionone [FL-no: 07.041] 
• P-Mentha-1,4(8)-dien-3-one [FL-no: 07.127] 
• 4,4a,5,6-Tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.136] 
• 4-(2,5,6,6-Tetramethyl-1-cyclohexenyl)but-3-en-2-one [FL-no: 07.200] 
• beta-Ionyl acetate [FL-no: 09.305] 
• Maltyl isobutyrate [FL-no: 09.525] 
 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substance. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
The European Commission requests European Food Safety Authority to carry out a safety assessment 
on the following 12 flavouring substances: 4-(2,2,6-trimethyl-1-cyclohexenyl)but3-en-2-ol [FL-no: 
02.106], beta-ionone [FL-no: 07.008], methyl-beta-ionone [FL-no: 07.010], maltol [FL-no: 07.014], 
beta-isomethylionone [FL-no: 07.041], nootkatone [FL-no: 07.089], 2,6,6-trimethylcyclohex-2-en-1,4-
dione [FL-no: 07.109], p-mentha-1,4(8)-dien-3-one [FL-no: 07.127], 4,4a,5,6-tetrahydro-7-
methylnapthalen-2(3H)-one [FL-no: 07.136], 4-(2,5,6,6-tetramethyl-1-cyclohexenyl)but-3-en-2-one 
[FL-no: 07.200], beta-ionyl acetate [FL-no: 09.305], maltyl isobutyrate [FL-no: 09.525] in accordance 
with Commission Regulation (EC) No 1565/2000. 
 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5  Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1-161. 
6  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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INTERPRETATION OF THE TERMS OF REFERENCE  
Nootkatone [FL-no: 07.089] and 4,4a,5,6-tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.136] 
were first allocated to FGE.213Rev1 for evaluation with respect to genotoxicity. Based on the new 
genotoxicity data submitted, the Panel concluded that [FL-no: 07.089] and [FL-no: 07.136] do not 
give rise to concern with respect to genotoxicity and can accordingly now be evaluated through the 
Procedure in FGE.87Rev2. 
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case, the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006b). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram (µg)/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
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information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the 46th meeting be amended to 
include the last step on the right-hand side of the original procedure (“Do the condition of use result in 
an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the Evaluation of the Substances in the Present FGE  
At its 63rd meeting the JECFA evaluated a group of 32 flavouring substances consisting of monocyclic 
and bicyclic secondary alcohols, ketones and related esters. Three substances were not in the Register, 
and six are α,β-unsaturated ketones or precursors for such and these will be or have been considered 
together with other α,β unsaturated substances aldehydes and ketones (EFSA, 2008b) in FGE.211, 
FGE.212 and FGE.213 and revisions thereof. One is an ether [FL-no: 16.088] considered in a revision 
of FGE.59 (FGE.59Rev1). Six are monocyclic secondary alcohols, ketones and related esters 
considered in FGE.56. Finally, the JECFA evaluated substance (1R)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-one (camphor [FL-no: 07.215]), which the Panel has evaluated in a 
separate Opinion (EFSA, 2008c). The remaining 15 flavouring substances were considered by EFSA 
in FGE.87 (EFSA, 2008a). 
The first revision of FGE.87, FGE.87Rev1 included the consideration of additional two substances 
[FL-no: 02.100 and 02.101]. These two substances are precursors for α,β-unsaturated ketones and 
were originally allocated to FGE.211 and FGE.212, respectively. Since the publication of FGE.87, the 
EU production volumes were provided for two substances, [FL-no: 09.153 and 09.319] for which the 
evaluation could not be finalised due to lack of these data. Based on these newly submitted EU 
production volumes the substances have already been evaluated in FGE.96 (EFSA, 2010), but for the 
sake of completion, the information has also been included here as well. Finally, new information on 
the stereoisomeric composition has been provided for 13 substances [FL-no: 02.016, 02.038, 02.059, 
07.159, 09.017, 09.082, 09.131, 09.153, 09.176, 09.218, 09.319 and 09.456 and 09.457] since the 
publication of FGE.87 (EFFA, 2010a, 2011). 
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FGE Opinion adopted   Link No. of 
substances 
FGE.87 22 May 2008 http://www.efsa.europa.eu/en/efsajournal/pub/746.htm 15 
FGE.87Rev1 1 February 2012 http://www.efsa.europa.eu/en/efsajournal/doc/2564.pdf 17 
FGE.87Rev2 2014  19 
The present revision of FGE.87 (FGE.87Rev2) concerns the consideration of two JECFA-evaluated 
substances nootkatone and 4,4a,5,6-tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.089 and 
07.136]. 
They were both evaluated by the JECFA at its 63rd meeting together with other monocyclic and 
bicyclic secondary alcohols, ketones and related esters. Both are α,β-unsaturated alicyclic ketones and 
were originally allocated to and evaluated in FGE.213Rev1 (EFSA CEF Panel, 2014b) in which they 
were considered not to be of concern with respect to genotoxicity. The Panel concluded that the 
substances could be included in the present FGE.87Rev2.  
For two substances [FL-no: 02.100] and [FL-no: 02.101] the information on stereoisomeric 
composition has been received and included in this FGE. 
2. Presentation of the Substances in the JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA Status 
The JECFA has at the 63rd meeting evaluated a group of 32 flavouring substances consisting of 
monocyclic and bicyclic secondary alcohols, ketones and related esters (JECFA, 2006a). 
2.1.2. EFSA Considerations 
Three of the 32 JECFA evaluated substances are not included in the Register, alpha-isomethylionyl 
acetate (JECFA-no: 1410), d,l-menthol-(±)-propylene glycol carbonate (JECFA-no: 1413) and l-
monomenthyl glutarate (JECFA-no: 1414). 
Six of the 32 JECFA evaluated substances are α,β-unsaturated [FL-no: 02.100, 02.101, 07.089, 
07.136, 07.140 and 09.305] and will be or have been evaluated together with other α,β-unsaturated 
aldehydes and ketones (EFSA, 2008b). However, four of these α,β-unsaturated substances [FL-no: 
02.100, 02.101, 07.089 and 07.136] have been considered with respect to genotoxicity in FGE.211 
(EFSA CEF Panel, 2011), FGE.212Rev2 (EFSA CEF Panel, 2014a) and FGE.213Rev1 (EFSA CEF 
Panel, 2014b) where the Panel concluded that the data available did rule out the concern for 
genotoxicity and thus concluded that these four substances can be evaluated through the Procedure in 
FGE.87. 
One of the JECFA evaluated substances is an ether [FL-no: 16.088] which is considered together with 
other ethers in a revision of FGE.59 (FGE.59Rev1). Six of the JECFA evaluated substances are 
monocyclic secondary alcohols, ketones and related esters and are considered in FGE.56. Finally, the 
JECFA evaluated substance, (1R)-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one (camphor [FL-no: 
07.215]), has been evaluated by the Panel in a separate Opinion (EFSA, 2008c). 
This consideration will therefore deal with 19 bicyclic secondary alcohols, ketones and related esters 
consisting of the 15 substances originally considered in FGE.87 and the four α,β-unsaturated 
substances, which have been cleared for concern for genotoxicity. The Panel concluded that all 
substances in the JECFA flavouring group of bicyclic secondary alcohols, ketones and related esters 
are structurally related to the group of four bicyclic secondary alcohols, ketones and related esters 
evaluated by EFSA in FGE.47Rev1. 
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2.2. Isomers 
2.2.1. Status 
All 19 substances have one or more chiral centres (see Table 1). 
2.2.2. EFSA Considerations 
The available specifications are considered adequate for all 19 substances.  
For the two stereoisomeric substances [FL-no: 07.153 and 09.269] with one chiral centre, the CAS 
register number (CASrn) is considered to cover the stereoisomeric composition. 
2.3. Specifications 
2.3.1. Status 
JECFA specifications are available for all substances (JECFA, 2005a).  
2.3.2. EFSA Considerations 
The information provided is adequate for all substances.  
3. Intake Estimation 
3.1. Status 
For 18 substances evaluated through the JECFA Procedure production figures are available for the 
EU. No EU production volume is available for the flavouring substance 4,4a,5,6-tetrahydro-7-
methylnapthalen-2(3H)-one [FL-no: 07.136] (see Table 1). 
3.2. EFSA Considerations 
For the flavouring substance 4,4a,5,6-tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.136] no EU 
production volume is available to calculate an MSDI exposure estimate. For all substances, use levels 
are needed to calculate the mTAMDIs. 
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Table 1:  Estimated intakes based on the MSDI- and the mTAMDI approach – FGE.87Rev2 
FL-no EU Register name MSDI – EU 
(µg/capita/day) 
MSDI – USA 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
02.016 Borneol 130 23  Class I 1800 
02.038 Fenchyl alcohol 55 17  Class I 1800 
02.059 Isoborneol 21 0.07  Class I 1800 
02.100 Pinocarveol 0.012 0.01  Class I 1800 
02.101 Pin-2-en-4-ol 0.012 0.2  Class I 1800 
09.017 Bornyl acetate 18 3  Class I 1800 
09.082 Bornyl formate 1.2 0.09  Class I 1800 
09.131 Isobornyl propionate 2.6 0.007  Class I 1800 
09.153 Bornyl valerate 3.7 5  Class I 1800 
09.176 Isobornyl formate 0.61 0.4  Class I 1800 
09.218 Isobornyl acetate 890 236  Class I 1800 
09.269 Fenchyl acetate 2.9 0.07  Class I 1800 
09.319 Bornyl butyrate 6.1 9  Class I 1800 
09.456 Bornyl isovalerate 0.12 0.5  Class I 1800 
09.457 Isobornyl isovalerate 0.012 0.08  Class I 1800 
07.089 Nootkatone 130 20  Class II 540 
07.136 4,4a,5,6-Tetrahydro-7-
methylnapthalen-2(3H)-
one 
 0.04  Class II 540 
07.153 1,10-Dihydronootkatone 0.24 0.9  Class II 540 
07.159 d-Fenchone 6.3 5  Class II 540 
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SUMMARY OF SPECIFICATION DATA 
Table 2:  Specification Summary of the Substances in the JECFA Flavouring Group of Bicyclic Secondary Alcohols, Ketones and Related 
Esters (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register 
name 
Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec. 
gravity (e) 
EFSA comments 
02.016 
1385 
Borneol 
HO
_____
OH
_____
 
2157 
64 
507-70-0 
Solid 
C10H18O 
154.25 
Very slightly 
soluble 
Soluble 
n.a. 
202 
IR 
97 % 
n.a. 
n.a. 
 
Racemate (±) = DL-
Borneol (EFFA, 
2010a). CASrn refers 
to (1R,2S,4R)-rel. 
Register name to be 
changed to DL-
Borneol (EFFA, 
2011).  According to 
JECFA ”Min. Assay 
value may incl. 
Isoborneol, other 
isomers of borneol, 
trace amounts of 
fenchyl alcohol & 
other C10H18O 
compounds”. 
02.038 
1397 
Fenchyl alcohol 
OH
 
2480 
87 
1632-73-1 
Solid 
C10H18O 
154.25 
Very slightly 
soluble 
Soluble 
n.a. 
35-40 
IR 
97 % 
n.a. 
n.a. 
 
Racemate (EFFA, 
2010a). According to 
JECFA "Min. Assay 
value is (97 %) of 
C10H18O which may 
include small amounts 
of borneol and 
isoborneol". 
02.059 
1386 
Isoborneol HO
_____
OH
_____
 
2158 
2020 
124-76-5 
Solid 
C10H18O 
154.25 
Very slightly 
soluble 
Soluble 
n.a. 
212-214 
IR 
92 % 
n.a. 
n.a. 
 
Racemate (±) = DL-
isoborneol (EFFA, 
2011). CASrn in 
Register refers to 
(1R,2R,4R)-rel. 
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Table 2:  Specification Summary of the Substances in the JECFA Flavouring Group of Bicyclic Secondary Alcohols, Ketones and Related 
Esters (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register 
name 
Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec. 
gravity (e) 
EFSA comments 
Register name to be 
changed to DL-
Isoborneol (EFFA, 
2011).  According to 
JECFA: Min. assay 
value is ”92 %” and 
secondary 
components ”3-5 % 
borneol”. 
02.100 
1403 
Pinocarveol   
HO
 
3587 
10303 
5947-36-4 
Liquid 
C10H16O 
152.24 
Insoluble 
Soluble 
210 
 
NMR 
95 % 
1.445-
1.451 
0.977-
0.983 
 
Racemate (EFFA, 
2014). 
02.101 
1404 
Pin-2-en-4-ol  HO
 
3594 
10304 
473-67-6 
Solid 
C10H16O 
152.24 
Very slightly 
soluble 
Soluble 
n.a. 
63-67 
NMR 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 
2014). 
07.089 
1398 
Nootkatone O
 
3166 
11164 
4674-50-4 
Liquid 
C15H22O 
218.35 
Slightly 
soluble 
Soluble 
73-103 (1 hPa) 
 
NMR 
93 % 
1.510-
1.523 
1.003-
1.032 
 
(+)-Nootkatone which 
refers to the 
(4R,4aS,6R)-isomer 
(EFFA, 2014). 
According to JECFA: 
Min. assay value is 
”93 %” and secondary 
components ”2-3 % 
dihydronootkatone”. 
07.136 
1405 
4,4a,5,6-
Tetrahydro-7-
methylnapthalen-
2(3H)-one 
O
 
3715 
 
34545-88-
5 
Solid 
C11H14O 
162.23 
Insoluble 
Soluble 
n.a. 
36-37 
IR 
99 % 
n.a. 
n.a. 
 
Racemate (EFFA, 
2014). Name to be 
changed to: 4,4a,5,6-
Tetrahydro-7-
methylnaphthalen-
2(3H)-one 
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Table 2:  Specification Summary of the Substances in the JECFA Flavouring Group of Bicyclic Secondary Alcohols, Ketones and Related 
Esters (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register 
name 
Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec. 
gravity (e) 
EFSA comments 
07.153 
1407 
1,10-
Dihydronootkaton
e 
O
 
3776 
 
20489-53-
6 
Liquid 
C15H24O 
220.36 
Very slightly 
soluble 
Soluble 
100-104(0.09hPa 
 
NMR 
90 % 
1.502-
1.508 
0.975-
0.988 
 
CASrn in Register 
refers to 
(4R,4aS,6R,8aS)-
stereoisomer. 
According to JECFA 
”Min. assay value is 
(90 %) and secondary 
components (5-6% 
nootkatone)”. 
 
07.159 
1396 
d-Fenchone 
O
 
2479 
551 
4695-62-9 
Liquid 
C10H16O 
152.24 
Insoluble 
Soluble 
192 
 
IR 
97 % 
1.460-
1.467 
0.940-
0.948 
 
D-(+)-Fenchone 
(EFFA, 2010a). 
CASrn in Register 
refers to (1S,4R)-
isomer. According to 
JECFA ”Min. Assay 
value is ”97 % of 
C10H16O” which 
may include small 
amounts of d-
camphor”. 
 
09.017 
1387 
Bornyl acetate 
O
O
O
O
 
2159 
207 
76-49-3 
Liquid 
C12H20O2 
196.29 
Slightly 
soluble 
Soluble 
226 
25 
IR 
98 % 
1.462-
1.466 
0.981-
0.985 
 
Racemate (±) = DL-
Bornyl acetate 
(EFFA, 2010a). 
CASrn in Register 
refers to (1R,2S,4R)-
rel. Register name to 
be changed to DL-
Bornyl acetate 
(EFFA, 2011). 
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Table 2:  Specification Summary of the Substances in the JECFA Flavouring Group of Bicyclic Secondary Alcohols, Ketones and Related 
Esters (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register 
name 
Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec. 
gravity (e) 
EFSA comments 
According to JECFA 
"Min. Assay value is 
98 % and may include  
isobornyl acetate and 
other bornyl acetate 
isomers".  
09.082 
1389 
Bornyl formate O
_____O
O
_____ O
 
2161 
349 
7492-41-3 
Liquid 
C11H18O2 
182.26 
Slightly 
soluble 
Soluble 
106-108 (27hPa) 
 
NMR 
95 % 
1.466-
1.472 
1.007-
1.013 
(20°) 
 
Racemate (±) = DL-
Bornyl formate 
(EFFA, 2011). CASrn 
in Register refers to 
(1R,2S,4R)-rel. 
Register name to be 
changed to DL-
Bornyl formate 
(EFFA, 2011). 
 
09.131 
1391 
Isobornyl 
propionate 
O
_____O
O
_____ O
 
2163 
412 
2756-56-1 
Liquid 
C13H22O2 
210.32 
Soluble 
Soluble 
245 
 
NMR 
97 % 
1.461-
1.465 
0.968-
0.971 
 
Racemate (±) = DL-
Isobornyl propionate 
(EFFA, 2010a). 
CASrn in Register 
refers to (1R,2R,4R)-
rel.Register name to 
be changed to DL-
Isobornyl propionate 
(EFFA, 2011). 
According to JECFA 
"Min. Assay value 
may include small 
amounts of bornyl 
propionate".  
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Table 2:  Specification Summary of the Substances in the JECFA Flavouring Group of Bicyclic Secondary Alcohols, Ketones and Related 
Esters (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register 
name 
Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec. 
gravity (e) 
EFSA comments 
09.153 
1392 
Bornyl valerate O
_____
O O
 
2164 
471 
7549-41-9 
Liquid 
C15H26O2 
238.37 
Insoluble 
Soluble 
136-137 (16hPa) 
 
NMR 
96 % 
1.459-
1.465 
0.957-
0.963 
 
Racemate (±) = DL-
Bornyl valerate 
(EFFA, 2010a). 
CASrn in Register 
refers to (1R,2S,4R)-
rel. Register name to 
be changed to DL-
Bornyl valerate 
(EFFA, 2011). 
 
09.176 
1390 
Isobornyl formate O
_____O
O
_____ O
 
2162 
565 
1200-67-5 
Liquid 
C11H18O2 
182.26 
Slightly 
soluble 
Soluble 
94-95 (20 hPa) 
 
NMR 
96 % 
1.469-
1.473 
1.011-
1.017 
 
Racemate (±) = DL- 
Isobornyl formate 
(EFFA, 2010a). 
CASrn in Register 
refers to (1R,2R,4R)-
rel. Register name to 
be changed to DL-
Isobornyl formate 
(EFFA, 2011). 
According to JECFA: 
Min. Assay value 
”may include small 
amounts of bornyl 
formate”. 
 
09.218 
1388 
Isobornyl acetate O
_____O
O
_____ O
 
2160 
2066 
125-12-2 
Liquid 
C12H20O2 
196.29 
Insoluble 
Soluble 
227 
 
IR 
97 % 
1.462-
1.465 
0.979-
0.984 
 
Racemate (±) = DL-
Isobornyl acetate 
(EFFA, 2010a). 
CASrn in Register 
refers to (1R,2R,4R)-
rel. Register name to 
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Table 2:  Specification Summary of the Substances in the JECFA Flavouring Group of Bicyclic Secondary Alcohols, Ketones and Related 
Esters (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register 
name 
Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec. 
gravity (e) 
EFSA comments 
be changed to DL-
Isobornyl acetate 
(EFFA, 2011). 
According to JECFA 
”Min. Assay value 
may include small 
amounts of bornyl 
acetate”. 
 
09.269 
1399 
Fenchyl acetate 
O
O
 
3390 
11769 
13851-11-
1 
Liquid 
C12H20O2 
196.29 
Slightly 
soluble 
Soluble 
220 
 
NMR 
98 % 
1.456-
1.462 
0.973-
0.979 
 
Racemate. (CASrn in 
Register refers to the 
racemate). 
 
09.319 
1412 
Bornyl butyrate O
_____
O
O
O
 
3907 
 
13109-70-
1 
Liquid 
C14H24O2 
224.34 
Slightly 
soluble 
Soluble 
247 
 
MS 
97 % 
1.462-
1.469 
0.981-
0.991 
 
Racemate (±) = DL-
Bornyl butyrate. 
CASrn in Register 
refers to (1R,2S,4R)-
rel. Register name to 
be changed to DL-
Bornyl butyrate 
(EFFA, 2011). 
 
09.456 
1393 
Bornyl isovalerate O
O
O
_____ O
 
2165 
451 
76-50-6 
Liquid 
C15H26O2 
238.37 
Insoluble 
Soluble 
260 
 
NMR 
97 % 
1.458-
1.461 
0.944-
0.947 
 
Racemate (±) = DL-
Bornyl isovalerate. 
CASrn in Register 
refers to (1R,2S,4R)-
rel. Register name to 
be changed to DL-
Bornyl isovalerate 
(EFFA, 2011). 
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Table 2:  Specification Summary of the Substances in the JECFA Flavouring Group of Bicyclic Secondary Alcohols, Ketones and Related 
Esters (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register 
name 
Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec. 
gravity (e) 
EFSA comments 
09.457 
1394 
Isobornyl 
isovalerate 
O
O
O
_____ O
 
2166 
452 
7779-73-9 
Liquid 
C15H26O2 
238.37 
Insoluble 
Soluble 
266-269 
 
NMR 
96 % 
1.463-
1.469 
0.900-
0.906 
 
Racemate (±) = DL-
Isobornyl isovalerate. 
CASrn in Register 
refers to (1R,2R,4R)-
rel. Register name to 
be changed to DL-
Isobornyl isovalerate 
(EFFA, 2011). 
 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
n.a.  not applicable.      
Flavouring Group Evaluation 87 Revision 2 
 
EFSA Journal 2014;12(10):3864 19 
4. Genotoxicity Data 
4.1. Genotoxicity Studies - Text Taken7 from the JECFA (JECFA, 2006a) 
Tests for genotoxicity in vitro and in vivo using standardized protocols have been used to study two 
representative members [FL-no: 02.016 and 09.131] of the bicyclic secondary alcohols, ketones and 
related esters group used as flavouring agents. 
In vitro 
Two members of this group (borneol, [FL-no: 02.016] and isobornyl propionate, [FL-no: 09.131]) 
consistently gave negative results in the Ames assay when incubated at a concentration of up to 5000 
µg/plate with a variety of Salmonella typhimurium strains including TA97, TA98, TA100, TA1535, 
TA1537 and TA1538 with or without metabolic activation (Simmon et al., 1977; Wild et al., 1983; 
Azizan and Blevins, 1995). 
Borneol [FL-no: 02.016] showed no mutagenic activity when tested in Escherichia coli WP2 uvrA at 
concentrations of up to 3200 µg/plate (Yoo, 1986). 
In the Rec-assay, borneol [FL-no: 02.016] was reported to induce growth inhibition in Bacillus subtilis 
strain M45- when tested at concentrations of up to 10 mg/disc (Yoo, 1986). This test has very limited 
relevance for the genotoxicity evaluation. 
In vivo 
The potential of isobornyl propionate [FL-no: 09.131] to induce sex-linked recessive lethal mutations 
in adult Drosophila melanogaster was studied in a Basc test. No increased frequency of mutation was 
observed in flies fed with isobornyl propionate [FL-no: 09.131] in a 10 mmol/l solution for 3 days 
(Wild et al., 1983). 
In the test for micronucleus formation, groups of NMRI mice given isobornyl propionate [FL-no: 
09.131] at a dose of 841, 1893 or 2944 mg/kg body weight (bw) by intraperitoneal administration 
showed no increase in micronucleated erythrocytes in samples of bone marrow, 30 hours after 
administration (Wild et al., 1983). 
Conclusion on genotoxicity 
The testing of these representative bicyclic secondary alcohols, ketones and related esters in bacterial 
(Ames assay) and mammalian (micronucleus formation) in vivo systems showed no evidence of 
genotoxic potential, and these results are further supported by the lack of positive findings in the 
Drosophila Basc test. These data are supported by the lack of genotoxic potential of the related α,β-
unsaturated monocyclic ketones, isophorone [FL-no: 07.126] and d-carvone [FL-no: 07.146] and l-
carvone [FL-no: 07.147]. These substances were evaluated by JECFA to be of no safety concern but 
have also been evaluated by EFSA in FGE.212Rev2 to be of no concern with respect to genotoxicity 
(see section 4.4). 
For a summary of in vitro/in vivo genotoxicity data considered by the JECFA, see Table 3. 
4.2. Genotoxicity Studies - Text Taken8 from EFSA FGE.47Rev1 (EFSA CEF Panel, 2012) 
No in vitro / in vivo genotoxicity data are available for the candidate substances in FGE.47. 
                                                     
7 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
8 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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4.3. Genotoxicity Studies - Text Taken from FGE.211 (EFSA CEF Panel, 2011) 
The following text is taken from FGE.211 and is relevant for the evaluation of pinocarveol [FL no: 
02.100], which was one of the four substances in subgroup 2.5 of FGE.19 (FGE.211) for which a 
conclusion of no concern for genotoxicity was reached. 
The Industry has submitted data concerning genotoxicity studies for a representative substance for this 
subgroup 2.5 of FGE.19, 1(7),8-p-menthadien-2-yl acetate [FL-no: 09.930] (structurally related to 
1(7),8-p-menthadien-2-one). 
In vitro data 
The newly available data comprise a bacterial reverse mutation assay and an in vitro micronucleus 
assay with human peripheral blood lymphocytes. The genotoxicity assays have been performed on a 
commercial mixture of the representative substance 1(7),8-p-menthadien-2-yl acetate and a positional 
isomer, carvyl acetate. Carvyl acetate can be hydrolysed following oxidation to carvone, which has 
been evaluated by EFSA in FGE.212 (EFSA, 2009) and NTP (NTP, 1990) as non-genotoxic. The 
highest concentration of d-carvone that could be tested without cytotoxicity was 333 µg/plate 
(Mortelmans et al., 1986), i.e. the cytotoxicity was in the same range as observed for the mixture of 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate. The Panel concluded that testing the commercial 
mixture of 1(7),8-p-menthadien-2-yl acetate/carvyl acetate for genotoxicity allows the evaluation of 
the genotoxic potential of 1(7),8-p-menthadien-2-yl acetate. The concentrations reported in Table 3 (in 
FGE.211) are for the mixture of substances. 
Bacterial Reverse Mutation Assay 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate was tested for mutagenic activity according to OECD 
guideline 471 and in compliance with GLP (Beevers, 2010). The test material exhibited a marked 
toxicity as indicated by thinning of the background lawn, reduced revertant counts and complete 
killing of test bacteria. However, the Panel considered the remaining number of concentrations 
without signs of toxicity sufficient to draw a conclusion on mutagenicity in this system (for details see 
FGE.211 Table 3).  
Overall, the Panel concluded that there was no evidence of mutagenic activity of 1(7),8-p-menthadien-
2-yl acetate/carvyl acetate at concentrations up to those causing bactericidal effects. 
In vitro Micronucleus Test 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate was tested for induction of micronuclei in human 
peripheral blood lymphocytes according to OECD guideline 487 and in compliance with GLP 
(Whitwell, 2010). The Panel considered that acceptable levels of cytotoxicity as judged upon the 
replication index were achieved at the top concentrations (for details see FGE.211 Table 3).  
Overall, the Panel concluded that there was no evidence of chromosomal damage or aneuploidy, as 
evidenced by no increase in levels of micronucleated binucleate cells (MNBN) in the presence or 
absence of S9 metabolic activation. 
Discussion of Mutagenicity/Genotoxicity Data 
The commercial mixture of the representative substance 1(7),8--p- -menthadien-2-yl acetate and a 
positional isomer, carvyl acetate was tested for all three genetic endpoints: gene mutations, structural 
and numerical chromosomal aberrations. The test material did not induce gene mutations in bacteria 
and was not clastogenic and/or aneugenic in mammalian cells in vitro. Although this commercial 
mixture was cytotoxic at high concentrations the remaining concentrations without signs of toxicity 
provide a valid data set. 
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Conclusion 
The in vitro genotoxicity data on the commercial mixture of the representative substance 1(7),8-p-
menthadien-2-yl acetate [FL-no: 09.930] and a positional isomer, carvyl acetate do not indicate 
genotoxic potential. Accordingly the four substances in this subgroup 2.5 of FGE.19 (FGE.211) would 
be of no safety concern with respect to genotoxicity, and will then be evaluated through the Procedure. 
4.4. Genotoxicity Studies - Text Taken from FGE.212Rev2 (EFSA CEF Panel, 2014a) 
The following text is taken from FGE.212Rev2 and is relevant for the evaluation of pin-2-en-4-ol [FL 
no: 02.101], which was one of the isophorone-related substances in subgroup 2.6 of FGE.19 
(FGE.212Rev1) for which a conclusion of no concern for genotoxicity was reached. 
There are studies available for four substances in this FGE (FGE.212Rev2). For tetramethyl 
ethylcyclohexenone (mixture of isomers) [FL-no: 07.035] one in vitro and one in vivo study have been 
evaluated. 
Seven in vitro and three in vivo studies are available for 3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 
07.126] (isophorone). 
Three in vitro studies are available concerning d-carvone [FL-no: 07.146] and two in vitro studies 
concerning l-carvone [FL-no: 07.147]. 
Study validation and results are presented in Tables 5 and 6 of FGE.212Rev2. 
3,5,5 Trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) did not induce gene mutations in 
bacteria but it induced mutations in mammalian cells in a mouse lymphoma TK assay in the absence 
of metabolic activation (it was not tested in the presence of metabolic activation) (NTP, 1986). No 
mutations in the MLTK assay were observed in a study of O’Donoghue et al. (O’Donoghue et al., 
1988) at comparable concentrations. Isophorone induced chromosomal aberrations in Chinese hamster 
lung fibroblasts with and without metabolic activation (Matsuoka et al., 1996) and sister chromatid 
exchanges (SCE) in CHO cells without metabolic activation (Gulati et al., 1989). Chromosomal 
aberrations have not been observed in two other studies (Gulati et al., 1989; NTP, 1986); however, the 
validity of the results was limited because the types of aberrations were not reported. Isophorone did 
not induce unscheduled DNA synthesis (UDS) in rat hepatocytes in vitro. In vivo, isophorone was 
tested negative in a sex-linked recessive lethal mutation assay in Drosophila (Foureman et al., 1994) 
and in two micronucleus assays in mice (McKee et al., 1987; O’Donoghue et al., 1988). However, the 
Drosophila assay has only limited relevance and the micronucleus assays were of limited validity. 
Negative results were also observed with tetramethyl ethylcyclohexenone [FL-no: 07.035] in bacteria, 
in a sex-linked recessive lethal mutation assay in Drosophila (Wild et al., 1983) and in a mouse 
micronucleus assay (Wild et al., 1983); however, there was a mixture of isomers tested and the studies 
were only of limited validity.  
d-Carvone [FL-no: 07.146] was not mutagenic in bacteria but induced SCE and chromosomal 
aberrations in CHO cells in the presence and absence of metabolic activation, respectively (NTP, 
1990). 
Conclusion on Genotoxicity and Carcinogenicity (cited from FGE.212Rev2) 
The Panel concluded that 3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) is 
genotoxic in vitro while a final conclusion on the genotoxicity in vivo could not be drawn based on the 
data available. It is carcinogenic in male rats and male mice. It was also predicted to be genotoxic in 
one of the four MultiCASE models (while it was out of domain in the ISS model). 
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d-Carvone [FL-no: 07.146] is genotoxic in vitro while no in vivo data were available. d-Carvone, was 
not carcinogenic in mice and was predicted to be non-genotoxic in the four MultiCASE models (while 
it was out of domain in the ISS model). No data are available on l-carvone. However, in vivo studies in 
humans show that the metabolism of ingestion-correlated amounts of d- or l-carvone occurs via a 
major oxidative pathway of the isopropylene side chain yielding diol and two carboxylic acids, 
irrespective of the stereochemical difference between the two parent isomers of carvone (Engel, 2001). 
Accordingly, the results for d-carvone can be used for l-carvone as well. 
The negative results reported from in vivo studies on the genotoxicity of tetramethyl 
ethylcyclohexenone [FL-no: 07.035] were only of limited validity. 
Data submitted from Industry in reply to Genotoxicity Data requested in FGE.212 (cited from the 
FGE.212Rev2) 
Honma et al. (Honma et al., 1999a, b) found that isophorone did not clearly induce mutations in the 
mouse lymphoma assay (MLA) following 3 hour treatments, but observed that it was mutagenic after 
24 hour treatments in the absence of S9. Although only graphs are plotted, it seems that increases in 
mutation frequency (MF) that exceeded the Global Evaluation Factor (GEF) occurred at around 
1250‐1500 μg/ml where toxicity (by relative survival) reached 70‐90 %. 
The NTP conducted a mouse bone marrow chromosomal aberration (CA) study on isophorone. 
Groups of eight  male B6C3F1 mice (larger group sizes than required by OECD) were dosed i.p. with 
isophorone at 125, 250 and 500 mg/kg bw. The standard protocol for in vivo CA is not given on the 
NTP website. However, based on Shelby and Witt (Shelby and Witt, 1995), animals should have been 
sampled at 17 hour and, if negative, also at 36 hours. The data on the NTP website are only for bone 
marrow sampled at 36 hour. It is therefore possible that a 17 hours sample was also taken, and found 
to be negative, but the data have not been posted. Fifty cells per animal were scored for CA and no 
increases in CA were seen. No measures of toxicity were recorded, but i.p. dosing should have 
guaranteed systemic exposure. The control CA frequency was normal (2.75 %) and the positive 
control (dimethylbenzanthracene) produced a significant response in CA frequency.  
A DNA binding study was conducted in which F344‐rats and B6C3F1‐mice (the strains used in the 
NTP carcinogenicity study) were exposed to isophorone (Thier et al., 1990). Animals of both sexes 
were dosed once or five times by gavage with 500 mg/kg bw of unlabelled isophorone spiked with 
[1,3,5‐14C]‐isophorone (specific activity: 52 mCi per mmol, 1.92 GBq per mmol). An additional group 
of acute dosed male rats received undiluted 14C‐isophorone for increased sensitivity. Rats and mice 
were maintained for 24 hours in closed metabolic cages. Twenty four hours after exposure, livers and 
kidneys (the tumour target tissues) were removed from the animals. DNA was isolated through 
hydroxyapatite chromatography and radioactivity was measured by liquid scintillation counting. No 
positive controls were included. Also no untreated controls were included, but, except for the liver 
sample of one mouse in the five times dose group, radioactivity values were within 2σ of background 
(6 dpm). Radioactivity values therefore did not indicate significant attachment of radioactivity to 
DNA. From these results it can be concluded that neither isophorone nor its metabolites bind 
covalently to DNA. 
A study (Morishita et al., 1997) was designed to investigate whether isophorone and/or α2μ‐globulin9 
might be involved in the induction of preputial gland tumours in F‐344 rats (10/sex/dose group). A 
series of experiments was performed in order to study several parameters including: 
• Binding of isophorone to DNA of kidney and preputial gland. Groups of 10 male rats were dosed 
by gavage with 500 mg/kg of [14C]‐isophorone (specific activity 14.65 mCi/mmol; 100 
μCi/animal). Positive control animals were dosed with 3H‐labeled methyl nitrosourea. 
                                                     
9 Since interaction with α2µ-glubulin is not of direct relevance for the evaluation of genotoxic potential, this 
information is omitted from this study summary. 
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• DNA adduct detection by 32P‐postlabeling in young adult male and female rats (7 per group) dosed 
by gavage with 0, 250 or 500 mg/kg isophorone for five days. 
Extraction of preputial gland and kidney DNA from rats treated with single 500 mg/kg labeled doses 
yielded no evidence of isophorone binding to DNA, whereas the positive control showed significant 
binding to DNA of preputial gland and kidney. These negative results with isophorone were confirmed 
in the 32P ‐postlabeling assays.  
In addition Industry has also asked whether the information submitted for isophorone, (cyclohexenyl 
derivative), could also be applied to evaluate the genotoxic potential of the five-carbon membered ring 
substances (i.e. cyclopentenyl derivatives) in subgroup 2.6 (letter of EFFA to EFSA, dated 14/4-2010) 
(EFFA, 2010b). This request was supported by the argumentation that there is structural resemblance 
with respect to steric hindrance around the α,β-unsaturated double bond. In addition, Industry argued 
that the π-conjugation systems in these molecules is very nearly planar and that therefore the reactivity 
and genotoxic potentials of the five- and six-membered ring systems would be similar. No further data 
were provided to substantiate this argumentation. 
Discussion of the Additional Data (cited from the FGE.212Rev2) 
Conflicting results were reported in two valid studies with the mouse lymphoma assay (MLA): one 
negative (O’Donoghue et al., 1988) and one positive (NTP, 1986) at comparable concentrations. 
Mixed results were also reported in two studies of limited validity: one negative (Honma et al., 1999a) 
and one positive (Honma et al., 1999b). Another negative result was reported in a study (McKee et al., 
1987), the validity of which cannot be evaluated. In the light of the clearly negative results in two 
valid bacterial gene mutation tests (Ames test) and in a valid Sex Linked Recessive Lethal Mutations 
test (SLRL) in Drosophila, and taking into account the lack of specificity and high sensitivity of the 
MLA, overall the results presently available are considered of questionable relevance. The Panel 
agrees that isophorone demonstrates some genotoxic activity in vitro but that the new data demonstrate 
lack of clastogenicity in vivo. In addition, the new DNA-binding data from two separate studies 
provide convincing evidence that isophorone does not induce tumours via a genotoxic mechanism. On 
the basis of these data it may be argued that there is no need to perform further in vivo genotoxicity 
studies such as the Comet assay or bone marrow micronucleus test. Thus, based on the data available 
the Panel concluded that there is no concern with respect to genotoxicity of isophorone. 
Since based on the additional information the concern for the genotoxic potential for isophorone has 
been alleviated, The Panel concluded in FGE.212Rev2 that a genotoxic potential could also be ruled 
out for the other isophorone-related six-carbon members of this subgroup of FGE.19. 
Study validation and results are presented in Table 6 of FGE.212Rev2 (EFSA CEF Panel, 2014a). 
4.5. Genotoxicity Studies - Text Taken from FGE.213Rev1 (EFSA CEF Panel, 2014b) 
The following text is taken from FGE.213Rev1 and is relevant for the evaluation of nootkatone and 
4,4a,5,6-tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.089 and 07.136], which are two of the 
13 substances in subgroup 2.7 of FGE.19 (FGE.213Rev1) for which a conclusion of no concern for 
genotoxicity was reached. 
Bacterial Reverse Mutation Assay 
Nootkatone [FL-no: 07.089] was tested in S. typhimurium strains TA98, TA100, TA1535, TA1537 
and TA102 in the absence or presence of S9-mix (Marzin, 1998). A preliminary toxicity test to 
identify appropriate concentrations for the mutagenicity assays was performed in the absence and 
presence of S9-mix, and cytotoxicity was observed at 50 μg/plate in the absence of S9-mix and at 150 
μg/plate in the presence of S9-mix. In the first mutagenicity experiment using plate incorporation 
methodology the concentrations tested were 0.5, 1.5, 5, 15, and 50 μg/plate in the absence of S9-mix 
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metabolic activation, and 1.5, 5, 15, 50, and 150 μg/plate in the presence of S9-mix. In the second 
experiment the pre-incubation method was used and the concentrations were 0.5, 1.5, 5, 15, and 50 
μg/plate in the absence of S9-mix metabolic activation, and 0.5, 1.5, 5, 15, 50, and 150 μg/plate in the 
presence of S9-mix. Thus, the study design complied with current recommendations and an acceptable 
top concentration was achieved. There was no evidence of any mutagenic effect induced by 
nootkatone in any of the strains, either in the absence or presence of S9-mix. 
Micronucleus Assays 
Nootkatone [FL-no: 07.089] was evaluated in an in vitro micronucleus assay in human peripheral 
blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and 
absence of rat S9-mix fraction as an in vitro metabolising system (Stone, 2011b). Cells were 
stimulated for 48 hours with phytohaemagglutinin to produce exponentially growing cells, and then 
treated for 3 hours (followed by 21 hours recovery) with 0, 50, 70 or 80 µg/ml of nootkatone in the 
absence of S9-mix and 0, 160, 180 and 185 µg/ml in the presence of S9-mix, respectively. The levels 
of cytotoxicity (reduction in replication index) at the top concentrations were 60 and 58 % 
respectively. In a parallel assay, cells were treated for 24 hours with 0, 10, 15, 22 and 24 µg/ml of 
nootkatone in the absence of S9-mix with no recovery period. The top concentration induced 62 % 
cytotoxicity. There were two replicate cultures per treatment, and 1000 binucleate cells per replicate 
(i.e. 2000 cells per dose) were scored for micronuclei. The study design complies with current 
recommendations (OECD Guideline 487), and acceptable levels of cytotoxicity were achieved at the 
top concentrations used in all parts of the study. No evidence of chromosomal damage or aneuploidy 
was observed as frequencies of MNBN cells were not significantly different from concurrent controls 
and fell within historical control ranges for all treatments with nootkatone in the presence or absence 
of S9-mix metabolic activation (Stone, 2011). 
Study validation and results are presented in Table 8 of FGE.213Rev1 (EFSA CEF Panel, 2014b). 
4.6. EFSA Considerations  
For four of the candidate substances [FL-no: 02.100, 02.101, 07.089 and 07.136] it has been 
concluded in FGE.211, FGE.212Rev2 and FGE.213Rev1, respectively, that a concern for 
genotoxicity, indicated by the presence of a structural alert, could be ruled out based on experimental 
data for supporting substances. Thus, the Panel concluded that these substances can be evaluated 
through the Procedure in FGE.87. For the remaining 15 candidate substances in FGE.87 [FL-no: 
02.016, 02.038, 02.059, 07.153, 07.159, 09.017, 09.082, 09.131, 09.153, 09.176, 09.218, 09.269, 
09.319, 09.456 and 09.457], genotoxicity data are available on two substances [FL-no: 02.016 and 
09.131]. The genotoxic potential of these two substances could not be adequately assessed. However, 
the data available do not preclude the evaluation of these 15 candidate substances using the Procedure. 
5. Application of the Procedure 
5.1. Application of the Procedure to 19 Bicyclic Secondary Alcohols, Ketones and related 
Esters by the JECFA (JECFA, 2006a) 
According to the JECFA, 15 of the 19 substances belong to structural class I and four to structural 
class II using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded the 19 bicyclic secondary alcohols, ketones and related esters at step A3 in the 
JECFA Procedure, i.e. the substances are expected to be metabolised to innocuous products (step 2) 
and concluded that the intakes for all substances are below the thresholds for their structural classes I 
and II (step A3).  
In conclusion, the JECFA considered that the bicyclic secondary alcohols, ketones and related esters 
evaluated through the Procedure, were of no safety concern at the estimated levels of intakes based on 
the MSDI approach. 
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The evaluations of the 19 bicyclic secondary alcohols, ketones and related esters are summarised in 
Table 4. 
5.2. Application of the Procedure to Bicyclic Secondary Alcohols, Ketones and Related 
Esters by EFSA in FGE.47Rev1 (EFSA CEF Panel, 2012)  
For the safety evaluation of the six candidate substances from chemical group 7 and 8 the Procedure as 
outlined in Annex I was applied, based on the MSDI approach.  
Step 1 
Four candidate substances are classified into structural class I [FL-no: 02.119, 09.584, 09.848 and 
09.888] and two [FL-no: 07.171 and 07.196] into structural class II according to the decision tree 
approach presented by Cramer et al. (Cramer et al., 1978). 
Step 2 
All six candidate substances in this group are expected to be metabolised to innocuous products. The 
evaluation of these substances therefore proceeded via the A-side of the Procedure scheme. 
Step A3 
The candidate substances [FL-no: 02.119, 07.171, 07.196, 09.584, 09.848 and 09.888] have estimated 
European daily per capita intakes ranging from 0.011 to 34 µg. These intakes are below the threshold 
of concern of 1800 µg/person/day for structural class I and 540 µg/person/day for structural class II 
substances.  
Based on results of the safety evaluation sequence of the Procedure, these six candidate substances, 
proceeding via the A-side of the Procedure scheme, do not pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on the MSDI approach. 
The stepwise evaluations of the six substances are summarised in Table 5. 
5.3. EFSA Considerations 
The Panel agrees with the application of the Procedure as performed by the JECFA for the bicyclic 
secondary alcohols, ketones and related esters. EFSA also agrees with the conclusion reached at step 
A3 of the Procedure for 18 substances in FGE.87 that they do not pose a safety concern when used as 
flavouring substances at estimated levels of intake, based on the MSDI approach. For the flavouring 
substance 4,4a,5,6-tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.136] this conclusion could not 
be reached because no annual production volume for Europe is available for this substance. Therefore 
no exposure estimate (MSDI) can be calculated and the evaluation through the Procedure cannot be 
finalised.    
CONCLUSION  
The Panel concluded that all 19 substances in the JECFA flavouring group of bicyclic secondary 
alcohols, ketones and related esters are structurally related to the group of bicyclic secondary alcohols, 
ketones and related evaluated by EFSA in the Flavouring Group Evaluation 47, Revision 1 
(FGE.47Rev1). 
The Panel agrees with the application of the Procedure as performed by the JECFA for the bicyclic 
secondary alcohols, ketones and related esters. It was concluded at step A3 of the Procedure that 18 
substances do not pose a safety concern when used as flavouring substances at estimated levels of 
intake, based on the MSDI approach. For the flavouring substance 4,4a,5,6-tetrahydro-7-
methylnapthalen-2(3H)-one [FL-no: 07.136] this conclusion could not be reached and the evaluation 
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through the Procedure cannot be finalised, because no annual production volume for Europe is 
available for this substance, from which a MSDI value can be calculated. 
For all 19 substances use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessments and to finalise the evaluation. 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Specifications are 
available for all the materials of commerce, however, a production volume for EU for substance [FL-
no: 07.136] is not available, which precludes the finalisation of the evaluation by EFSA of this 
substance. 
For the remaining 18 JECFA–evaluated bicyclic secondary alcohols, ketones and related esters [FL-
no: 02.016, 02.038, 02.059, 02.100, 02.101, 07.089, 07.153, 07.159, 09.017, 09.082, 09.131, 09.153, 
09.176, 09.218, 09.269, 09.319, 09.456 and 09.457] the Panel agrees with the JECFA conclusion: “No 
safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach. 
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SUMMARY OF GENOTOXICITY DATA  
Table 3:  Genotoxicity Data (in vitro / in vivo) JECFA (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
02.016 
1385 
Borneol 
OH
_____
 
Reverse mutation S. typhimurium TA97, TA98, 
TA100 
1 mg/ml (1000 µg/ml) Negative1 (Azizan and Blevins, 1995) 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
≤ 5 mg/plate (5000 
µg/plate) 
Negative1 (Simmon et al., 1977) 
DNA repair B. subtilis M45- and H17+ ≤ 10 mg/disc Positive (Yoo, 1986) 
Mutation test E. coli WP2 uvrA (trp-) 0.4-3.2 mg/plate Negative (Yoo, 1986) 
09.131 
1391 
Isobornyl 
propionate 
O
_____O
 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
≤ 3.6 mg/plate  
(3600 µg/plate) 
Negative1 (Wild et al., 1983) 
07.012 
380 
Carvone 
 
Gene mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative (Florin et al., 1980) 
   DNA repair B. subtilis M45 (rec-) and H17 
(rec+) 
0.6 ml/disc Negative (Matsui et al., 1989) 
07.147 
380.2 
l-Carvone 
O
 
Gene mutation 
(preincubation) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
333 µg/plate Negative (Mortelmans et al., 1986) 
   Gene mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
333 µg/plate Negative (NTP, 1990) 
   Sister chromatid exchange Chinise hamster ovary cells 502 µg/plate Equivocal (NTP, 1990) 
   Chromosomal aberration Chinise hamster ovary cells 400 µg/plate Equivocal (NTP, 1990) 
07.126 
1112 
Isophorone 
 
Reverse mutation S. typhimurium TA97, TA98, 
TA100, TA1535, TA1537 
33 - 10000 mg/plate Negative1 (Mortelmans et al., 1986) 
   Mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
33 - 10000 mg/plate Negative1 (NTP, 1986) 
   Mutation L5178YTk+/– mouse 67 - 810 mg/ml Negative4 (McKee et al., 1987) 
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Table 3:  Genotoxicity Data (in vitro / in vivo) JECFA (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
lymphoma cells  
     130 - 1300 Negative5 (McKee et al., 1987) 
   Mutation L5178YTk+/– mouse 
lymphoma cells 
0.089 - 0.89 mg/ml Negative4 (O’Donoghue et al., 1988) 
      Negative5 (O’Donoghue et al., 1988) 
   Mutation L5178YTk+/– mouse 
lymphoma cells 
800 mg/ml6 Positive5 (McGregor et al., 1988) 
   Mutation L5178YTk+/– mouse 
lymphoma cells 
1200 mg/ml Negative4 (NTP, 1986) 
      Positive5  
   Chromosomal aberration Chinese hamster ovary cells 5 – 1600 mg/ml Negative1 (Gulati et al., 1989) 
      Positive4,7   
   Chromosomal aberration  Chinese hamster lung 
fibroblasts  
12005, 15004 mg/ml Positive1 (Matsuoka et al., 1996) 
     250 – 1000 mg/ml Negative1  
   Sister chromatid exchange Chinese hamster ovary cells 5 – 1600 mg/ml Positive4,7 (Gulati et al., 1989) 
   Sister chromatid exchange Chinese hamster ovary cells 160 – 1000 mg/ml Negative1 (NTP, 1986) 
   Unscheduled DNA 
synthesis 
Rat hepatocytes 0.005 – 0.4 ml/ml Negative1 (O’Donoghue et al., 1988) 
   Unscheduled DNA 
synthesis 
Rat hepatocytes 200 ml/ml Negative1 (McKee et al., 1987) 
In vivo 
09.131 
1391 
Isobornyl 
propionate 
O
_____O
 
Somatic mutation and 
recombination 
D. melanogaster 10 mmol/l (2103 µg/ml) Negative2 (Wild et al., 1983) 
Micronucleus formation Mouse bone marrow cells 841, 1893 and 2944 
mg/kg bw 
Negative3 (Wild et al., 1983) 
07.126 
1112 
Isophorone 
 
Sex-linked recessive lethal 
mutation 
D. melanogaster 20008 and 125003 ppm Negative (Foureman et al., 1994) 
   Micronucleus formation CD-1 mice 540 mg/kg bw Negative (McKee et al., 1987) 
   Micronucleus formation CD-1 mice 0.54 ml/kg bw Negative (O’Donoghue et al., 1988) 
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1 Tested with and without metabolic activation. 
2 Dose calculated based on the relative molecular mass of substance = 210.32. 
3 Administered via intraperitoneal injection. 
4 Without metabolic activation. 
5 With metabolic activation. 
6 Cytotoxic at next highest dose tested (1600 mg/ml). 
7 A positive response was obtained only in the absence of metabolic activation and only after additional culture time (6–13 h). 
8 Oral administration. 
 
No in vitro / in vivo genotoxicity data are available for the candidate substances in FGE.47Rev1 (EFSA CEF Panel, 2012). 
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SUMMARY OF SAFETY EVALUATIONS 
Table 4:  Summary of Safety Evaluation by the JECFA (JECFA, 2005b) 
FL-no 
JECFA
-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome on 
the named 
compound 
[(d) or (e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
02.016 
1385 
Borneol 
HO
_____
OH
_____
 
130 
23 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-Borneol. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
02.038 
1397 
Fenchyl alcohol 
OH
 
55 
17 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
02.059 
1386 
Isoborneol HO
_____
OH
_____
 
21 
0.07 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-
Isoborneol.   
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
02.100 
1403 
Pinocarveol 
HO
 
0.012 
0.01 
Class I 
A3: Intake 
below 
threshold 
d Evaluated in FGE.211, 
genotoxicity concern 
could be ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
02.101 
1404 
Pin-2-en-4-ol HO
 
0.012 
0.2 
Class I 
A3: Intake 
below 
threshold 
d Evaluated in 
FGE.212Rev1, 
genotoxicity concern 
could be ruled out. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.017 
1387 
Bornyl acetate 
O
O
O
O
 
18 
3 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-Bornyl 
acetate. 
No safety concern at the 
estimated level of intake 
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Table 4:  Summary of Safety Evaluation by the JECFA (JECFA, 2005b) 
FL-no 
JECFA
-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome on 
the named 
compound 
[(d) or (e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
based on the MSDI 
approach. 
 
09.082 
1389 
Bornyl formate O
_____O
O
_____ O
 
1.2 
0.09 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-Bornyl 
formate. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.131 
1391 
Isobornyl 
propionate 
O
_____O
O
_____ O
 
2.6 
0.007 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-
Isobornyl propionate. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.153 
1392 
Bornyl valerate O
_____
O
O
_____
O
 
3.7 
5 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-Bornyl 
valerate.   
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.176 
1390 
Isobornyl formate O
_____O
O
_____ O
 
0.61 
0.4 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-
Isobornyl formate.   
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.218 
1388 
Isobornyl acetate O
_____O
O
_____ O
 
890 
236 
Class I 
A3: Intake 
below 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
Register name to be 
changed to DL-
Isobornyl acetate.   
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Table 4:  Summary of Safety Evaluation by the JECFA (JECFA, 2005b) 
FL-no 
JECFA
-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome on 
the named 
compound 
[(d) or (e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
threshold approach. No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.269 
1399 
Fenchyl acetate 
O
O
 
2.9 
0.07 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.319 
1412 
Bornyl butyrate O
_____
O
O
_____
O
 
6.1 
9 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
CASrn in Register 
refers to (1R,2S,4R)-rel. 
Register name to be 
changed to DL-Bornyl 
butyrate. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.456 
1393 
Bornyl isovalerate O
_____O
O
_____ O
 
0.12 
0.5 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-Bornyl 
isovalerate.   
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.457 
1394 
Isobornyl 
isovalerate 
O
_____O
O
_____ O
 
0.012 
0.08 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Register name to be 
changed to DL-
Isobornyl isovalerate.  
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.089 
1398 
Nootkatone O
 
130 
20 
Class II 
A3: Intake 
below 
d Evaluated in 
FGE.213Rev1, 
genotoxicity concern 
No safety concern at the 
estimated level of intake 
based on the MSDI 
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Table 4:  Summary of Safety Evaluation by the JECFA (JECFA, 2005b) 
FL-no 
JECFA
-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome on 
the named 
compound 
[(d) or (e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
threshold could be ruled out. approach. 
07.136 
1405 
4,4a,5,6-
Tetrahydro-7-
methylnapthalen-
2(3H)-one 
O
 
 
0.04 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in 
FGE.213Rev1, 
genotoxicity concern 
could be ruled out. 
EU production volume 
is not available. This 
precludes the 
finalisation of the 
evaluation. 
07.153 
1407 
1,10-
Dihydronootkatone 
O
 
0.24 
0.9 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
CASrn refers to 
(4R,4aS,6R,8aS)-
stereoisomer. Register 
name to be changed 
accordingly.   
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.159 
1396 
d-Fenchone 
O
 
6.3 
5 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
(a): EU MSDI: Amount added to food as flavour in (kg / year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg/capita/day. 
(b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 5:  Summary of Safety Evaluation by the EFSA (FGE.47Rev1) (EFSA CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI a) 
(µg/capita/day) 
Class b) 
Evaluation procedure 
path c) 
Outcome on the 
named compound 
[d) or e)] 
Outcome on the 
material of 
commerce  
[f), g), or h)] 
Evaluation 
remarks 
02.119 
 
Cedrenol 
OH
 
34 
 
Class I 
A3: Intake below 
threshold 
d f i 
09.584 
 
Isobornyl isobutyrate 
O
O
O
O
 
0.085 
 
Class I 
A3: Intake below 
threshold 
d f  
09.848 
 
(1S-endo)-1,7,7-
Trimethylbicyclo[2.2.1]
heptan-2-ol acetate 
O
_____O
 
0.011 
 
Class I 
A3: Intake below 
threshold 
d f  
09.888 
 
Isobornyl 2-
methylbutyrate O
_____O
O
_____ O
 
0.061 
 
Class I 
A3: Intake below 
threshold 
d f  
07.171 
 
Isopinocamphone 
O
 
0.024 
 
Class II 
A3: Intake below 
threshold 
d f  
07.196 
 
Pin-2-en-4-one 
O  
15 
 
Class II 
A3: Intake below 
threshold 
d f j 
(a) EU MSDI: Amount added to food as flavour in (kg / year)  × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg/capita/day. 
(b) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d) No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e) Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f) No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
(i) Evaluated in FGE.211, genotoxicity concern could be ruled out. 
(j) Evaluated in FGE.212Rev1, genotoxicity concern could be ruled out. 
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DOCUMENTATION PROVIDED TO EFSA 
1. Beevers C, 2010. Reverse mutation in five histidine-requiring strains of Salmonella typhimurium. 
1(7),8-p-menthadien-2-yl acetate. Covance Laboratories Ltd, England. Study no. 8213039. April 
2010. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
2. EFFA (European Flavour Association), 2010a. EFFA Letters to EFSA for clarification of 
specifications and isomerism for which data were requested in published FGEs. 
3. EFFA (European Flavour Association), 2010b. EFFA letter to EFSA/Commission concerning: 
Submission of additional data related to FGE.19 subgroup 2.6. Dated 14 April 2010. 
FLAVIS/8.142. 
4. EFFA (European Flavour Association), 2011. E-mail from EFFA/DG SANCO to FLAVIS 
Secretariat, Danish Food Institute, Technical University of Denmark. Dated 14 September 2011. 
FGE.87 concerning correct chemical names. FLAVIS/8.133. 
5. EFFA (European Flavour Association), 2014. E-mail from EFFA to FLAVIS Secretariat, Danish 
Food Institute, Technical University of Denmark. Dated 1 July 2014. Information on substances 
[FL-no: 02.100, 02.101, 07.089, 07.136] in FGE.87Rev2. FLAVIS/8.250. 
6. Marzin D, 1998. Recherche de mutagenicite sur salmonella typhimurium his - selon la methode de 
B.N. Ames sur le produit ST14C97 [Bacterial reverse mutation assay of nootkatone (Ames test)]. 
Institut Pasteur de Lille. Rapport no. IPL-R980113/ST14C97/Firmenich Production. 29 Janvier 
1998. Unpublished report submitted by EFFA to FLAVIS Secretariat. (In French) 
7. Morishita K, Schoonhoven R and Swenberg JA, 1997. Mechanistic studies on isophorone and 
preputial gland carcinomas. Department of Environmental Sciences and Engineering, University 
of North Carolina, Chapel Hill, N.C. March 25, 1997. Unpublished report submitted by EFFA to 
FLAVIS secretariat. 
8. Stone V, 2011. Induction of micronuclei in cultured human peripheral blood lymphocytes. 
Nootkatone. Covance Laboratories Ltd. Study no. 8242980. June, 2011. Unpublished report 
submitted by EFFA to FLAVIS Secretariat. 
9. Whitwell J, 2010. Induction of micronuclei in cultured human peripheral blood lymphocytes. 
1(7),8-p-menthadien-2-yl acetate. Covance Laboratories Ltd, England. Study no. 822021. April 
2010. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
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ABBREVIATIONS 
 
BW  Body weight 
CAS  Chemical Abstracts Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations 
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation 
FLAVIS (FL)  Flavour Information System (database) 
GLP   Good Laboratory Practise 
GC-MS  Gas chromatography-mass spectrometry 
ID  Identity 
I.p.   Intraperitoneal 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI   Maximised Survey-derived Daily Intake 
mTAMDI  Modified Theoretical Added Maximum Daily Intake 
No   Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCR  Polymerase Chain Reaction 
SCE  Sister chromatic exchange 
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SCF  Scientific Committee on Food 
UDS  Unscheduled DNA synthesis 
WHO  World Health Organization 
